Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.25, near the low end of its 5-year range (0.00–1.28).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 0.64.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.64
DEBT TO EQUITY RATIO AVG 3Y
0.37
DEBT TO EQUITY RATIO AVG 5Y
0.25
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Passage Bio, Inc.
Market Cap
$13.40M
Debt to Equity Ratio
0.00
TTM Avg
0.64
3Y Avg
0.37
5Y Avg
0.25
Market Cap
$13.18M
Debt to Equity Ratio
0.11
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$13.48M
Debt to Equity Ratio
0.29
TTM Avg
0.66
3Y Avg
0.36
5Y Avg
0.25
Market Cap
$13.78M
Debt to Equity Ratio
0.63
TTM Avg
1.07
3Y Avg
0.83
5Y Avg
0.60
Market Cap
$13.93M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.03
5Y Avg
0.20
Market Cap
$14.01M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.60M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$12.66M
Debt to Equity Ratio
N/A
TTM Avg
3.67
3Y Avg
2.17
5Y Avg
1.48
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $13.40M | 0.00 | 0.64 | 0.37 | 0.25 |
| IN8bio, Inc. (INAB)vs › | $13.33M | 0.12 | 0.22 | 0.23 | 0.16 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.18M | 0.11 | 0.01 | 0.01 | 0.02 |
| Optimi Health Corp. (OPTH)vs › | $13.48M | 0.29 | 0.66 | 0.36 | 0.25 |
| Sintx Technologies, Inc. (SINT)vs › | $13.78M | 0.63 | 1.07 | 0.83 | 0.60 |
| Vyome Holdings, Inc. (HIND)vs › | $13.93M | 0.00 | 0.01 | 0.03 | 0.20 |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.01M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.60M | 0.01 | 0.00 | 0.00 | 0.00 |
| Cytosorbents Corporation (CTSO)vs › | $12.66M | N/A | 3.67 | 2.17 | 1.48 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.54M | 0.05 | 0.04 | 0.04 | 0.03 |
Debt/Equity
0.00
Current Ratio
1.22
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.49 |
| 2025-12-31 | 1.28 |
| 2025-09-30 | 0.78 |
| 2025-06-30 | 0.65 |
| 2025-03-31 | 0.54 |
| 2024-12-31 | 0.42 |
| 2024-09-30 | 0.36 |
| 2024-06-30 | 0.29 |
| 2024-03-31 | 0.25 |
| 2023-12-31 | 0.24 |
| 2023-09-30 | 0.21 |
| 2023-06-30 | 0.18 |
| 2023-03-31 | 0.16 |
| 2022-12-31 | 0.13 |
| 2022-09-30 | 0.12 |
| 2022-06-30 | 0.11 |
| 2022-03-31 | 0.10 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.00 |
